Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 24, 2026
Event: Entry into a Material Definitive Agreement (Warrant Inducement) and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Details
- Proceeds: The Company anticipates receiving approximately $4.9 million in gross proceeds from the exercise of existing warrants.
- Shares Exercised: 857,462 shares of common stock purchased by the Holder at an exercise price of $5.75 per share.
- New Securities Issued:
- Series E-1 Warrant: Up to 535,913 shares.
- Series E-2 Warrant: Up to 535,913 shares.
- New Warrant Exercise Price: $6.25 per share.
- Term: 5 years from the initial exercise date.
- Transaction Costs:
- Financial Advisor: Maxim Group LLC.
- Fee: 7.0% of total proceeds from the exercise of existing warrants.
- Expense Reimbursement: Up to $15,000.
Material Changes and Transaction Structure
The filing details a warrant inducement transaction where the Holder agreed to exercise existing Series D-1 and D-2 warrants in exchange for new Series E-1 and E-2 warrants. Key structural elements include:
- Beneficial Ownership Limitation: The Holder cannot exercise warrants if it results in beneficial ownership exceeding 4.99% or 9.99% (at the Holder's election) of outstanding shares.
- Registration Rights: The Company agreed to file a resale registration statement within 15 days and use commercially reasonable efforts to have it declared effective within 45 days (or 75 days if reviewed by the SEC).
- Redemption Rights: In the event of a fundamental transaction, the Series E-2 Warrant holder has the right to require the Company to purchase the warrant at its Black Scholes value. The Series E-1 Warrant does not include this right.
- Cashless Exercise: New Warrants may be exercised on a cashless basis only after six months if no effective registration statement is available for resale.
Guidance, Risks, and Contingencies
- Regulatory Risk: The New Warrants and underlying shares are issued under Section 4(a)(2) of the Securities Act and are not registered. They cannot be offered or sold in the U.S. absent registration or an exemption.
- Forward-Looking Statements: The filing notes that representations and warranties in the Inducement Letter are for risk allocation between parties and may not reflect materiality standards viewed by stockholders. Information may change after the date of the agreement.
- Emerging Growth Company Status: The Company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.
Investor Verification Checklist
- Verify the effectiveness of the Form S-3 registration statement (File No. 333-297760) for the resale of the 857,462 shares from the exercised warrants.
- Monitor the filing and effectiveness of the new Resale Registration Statement for the New Warrant Shares (due within 15-45 days of August 24, 2026).
- Confirm the actual cash proceeds received after deducting the 7.0% advisory fee and offering expenses.
- Review the impact of the new warrant issuance on the Company's capitalization and potential dilution, considering the 9.99% beneficial ownership limitation.
- Check for any subsequent press releases or filings regarding the status of the Black Scholes redemption right for the Series E-2 Warrants.